Advertisement

Child's Nervous System

, Volume 34, Issue 10, pp 1989–1996 | Cite as

Infections in the immunocompromised child

  • Llewellyn C. Padayachy
  • A. Graham Fieggen
Special Annual Issue

Abstract

Prevention and management of opportunistic infections in children is particularly relevant in an era demonstrating an increased prevalence of immunocompromising conditions. The presence of an unusual organism which results in serious infection in a child should therefore always raise the consideration of immune compromise. The more common opportunistic infections have become easier to recognize in recent times due to improved awareness and more refined diagnostic testing. Targeted treatment is usually followed by long-term prophylactic medication. The impact of these conditions on patient outcome is of clear significance and certainly warrants further discussion.

Keywords

Infection Immunocompromised child 

Introduction

Central nervous system (CNS) infections represent an increasing challenge in the management of immunocompromised children. The types of infection and their consequences usually reflect the nature and severity of the underlying immunodeficiency and the virulence of the organisms involved [1, 2]. The more common pathogens are easier to diagnosis and treat, whereas opportunistic infections are caused by more unusual microorganisms and tend to be more severe, longer lasting, and unpredictable, making management more complicated. Additional risk factors in immunocompromised patients include the presence of indwelling catheters, disruption of mucosal barriers, and the need for repeat surgery and adjunctive therapies [1, 3].

An underlying immunodeficiency should be considered when an unusual organism is identified as the pathogen. Immunocompromising conditions may be either congenital or acquired. Congenital conditions include B cell defects, T cell defects, combined B cell and T cell defects, macrophage, cytokine and miscellaneous defects, phagocyte dysfunction, and complement deficiencies [4]. Acquired conditions include malnutrition; viral infection, e.g., HIV; malignancy; drugs; trauma; metabolic disorders; and environmental exposure [5]. The most frequently implicated organisms in opportunistic CNS infections in immunocompromised children may be bacterial, parasitic, fungal, or viral species.

Bacterial infections

Infection with Mycobacterium tuberculosis remains a condition directly associated with poverty and socio-economic disparity. Most healthy individuals do not develop active disease, while HIV-infected patients are about six times more likely to develop TB and are particularly susceptible to extrapulmonary TB [6]. Primarily a pulmonary infection, about 95% of cases are contained by cell-mediated immunity, with spread to the CNS occurring in about 1% of cases [7, 8]. Tuberculous meningitis (TBM) in immunocompromised patients demonstrates higher drug resistance and mortality rates, attributed mostly to delayed diagnosis, which is common in most developing countries [9]. TBM is the commonest and most lethal neurologic presentation, but focal parenchymal lesions such as tuberculomas or tuberculous abscesses and tuberculous osteomyelitis, either of the skull or vertebrae (Pott’s disease), are also encountered. In TBM, there is a typically thick gelatinous exudate in the basal cisterns, leading to hydrocephalus and cerebrovascular inflammation and subsequent ischemia, raised intracranial pressure (ICP), and parenchymal injury [10, 11].

A positive history of TB contact with a positive tuberculin skin test or Mantoux is highly suggestive. Chest X-ray findings typical of pulmonary TB are well described, and the organism may be identified or cultured from sputum or gastric washings [12]. New molecular diagnostic tools like the Xpert MTB/RIF have been introduced and are being validated for CNS disease [4].

The typical imaging appearance of TBM is often described as a triad of contrast enhancement of the basal meninges with hydrocephalus and infarcts [5] (Fig. 1a, b). Hypodensities related to cerebral ischemia are common in the so-called TB zone, the vascular territory of the middle cerebral artery, involving the lenticulostriate and thalamoperforating vessels [8, 9].
Fig. 1

CT scan demonstrating a posterior fossa tuberculoma with compression of the fourth ventricle and associated obstructive hydrocephalus, (a) pre-contrast and (b) post-contrast

Treatment with four drugs for 6 months [10] is usually advocated, with some recommending 9–12 months [13, 14, 15]. Pyridoxine should be prescribed with INH to prevent peripheral neuropathy. Follow-up imaging is of value in detecting complications such as hydrocephalus and infarcts [15]. The optimal management of tuberculous hydrocephalus (TBH) is controversial with most institutions developing their own treatment algorithms with respect to the indications for surgery and the choice of operation [16, 17]. Ventriculo-peritoneal shunts (VPS) have been the most widely described option, though the reported complication rate has been high [18, 19, 20]. A selective approach of first inserting an external ventricular drain (EVD) as a temporary measure and then shunting those who responded favorably has been recommended [21, 22]. Endoscopic third ventriculostomy (ETV) in this setting has also been reported but can be technically quite challenging as the floor of the third ventricle is usually opaque and thickened with exudate and adhesions obscuring the pre-pontine cisternal space [18, 19, 20, 23] (Fig. 2). Some authors report greater success with ETV in chronic TBH when the acute exudate has resolved [16, 24, 25].
Fig. 2

Intraoperative endoscopic view of the thickened, opaque floor of the third ventricle in tuberculous meningitis

Small solitary lesions that present with seizures alone may be difficult to distinguish from cysticercal granulomas and in the absence of active tuberculosis elsewhere may not require treatment other than anticonvulsants; larger lesions should be treated with the standard four-drug regimen [8].

With appropriate antituberculous therapy, the majority of children with TBM survive, but long-term neurological and psychological outcome remains poor [13, 26].

Parasitic infestations

Parasitic infestation of the central nervous system affects millions of people, mostly in the developing world where poverty and related conditions prevail, although a change in the geographic distribution of these diseases has become more evident in the era of globalization [8].

Parasitic infestations can be broadly classified as protozoan (single-celled organisms) and metazoan/helminthic (complex, multicellular organisms).

Toxoplasma gondii is an obligate intracellular protozoan parasite with a worldwide distribution, first identified in the human retina [27, 28]. The increasing number of immunocompromised patients, either due to HIV infection or immunosuppression, has led to the emergence of toxoplasmosis as a potentially life-threatening opportunistic infection [29, 30].

In CNS infection, the cerebral gray matter is diffusely involved, resulting in meningoencephalitis and foci of perivascular inflammation, with basal ganglia and periventricular calcification reported in the fetus [31, 32]. In immunocompromised hosts, widespread necrotizing lesions may occur within the CNS and other organs [33]. In congenital toxoplasmosis, hydrocephalus may result from obstruction at the foramen of Monro or aqueduct of Sylvius. The disease in children occurs in three categories: congenital, postnatally acquired, and ocular.

Congenital toxoplasmosis is often subclinical but may present with fever, hydrocephalus, chorioretinitis, cerebral calcification, seizures, microcephaly, and an abnormal CSF (markedly raised protein and mononuclear pleocytosis) or systemic involvement such as hepatosplenomegaly and jaundice [34, 35]. The severity of the clinical disease in congenitally infected infants is inversely related to the gestational age at the time of maternal infection [29] and must be differentiated from other perinatal encephalopathies cause by cytomegalovirus, herpes simplex virus, rubella virus, and certain metabolic and storage diseases [36].

The diagnosis of congenital toxoplasmosis can be made through a combination of clinical examination, radiological features, CSF, and serological analysis, as well isolation of T. gondii from tissue or fluid specimens in acute infection [37, 38]. Repeat fetal ultrasound may demonstrate rapidly progressive, symmetrical ventricular dilatation as the most common finding. When fetal toxoplasmosis infection is confirmed, antibiotic treatment with sulfadiazine and pyrimethamine together with folinic acid has been recommended [36, 39], with prednisone if CSF protein is elevated or sight-threatening chorioretinitis occurs [36]. Untreated congenital toxoplasmosis has a poor prognosis, with prolonged treatment substantially improving the frequency and severity of neurological sequelae [40, 41]. Toxoplasmosis and coexistent HIV infection in children are rarer than in adults [42], especially since the advent of highly active antiretroviral therapy (HAART).

Hydrocephalus may be associated with congenital toxoplasmosis due to either obstruction at the outlet foramina and aqueduct of Sylvius as well as impaired absorption at the arachnoid villi [43, 44]. The nature of the hydrocephalus, i.e., obstructive or non-obstructive, has important implications regarding the treatment options.

Acquired toxoplasmosis remains asymptomatic in most cases. With CNS involvement, the predominant symptoms are headache, disorientation, and drowsiness, and it should be considered in the differential diagnosis whenever evidence of acute CNS disease occurs in immunocompromised patients [36].

Toxoplasmosis of the central nervous system occurs in up to 40% of all HIV infected patients and is the most common opportunistic infection to cause focal brain lesions [45, 46]. While often asymptomatic in children and adults, three different neurological patterns are evident in toxoplasmosis of the CNS, diffuse encephalitis with or without seizures, meningoencephalitis, and single or multiple mass lesions [47].

The diagnosis of toxoplasmosis of the CNS is made on history of exposure and risk factors, clinical examination, serological/CSF testing (where LP is safe), and radiological features. On radiological imaging, cerebral toxoplasmosis often appears as multiple lesions (> 5 lesions), demonstrates ring enhancement with contrast, is typically located in the basal ganglia or the gray-white matter interface, has minimal mass effect with mild edema, and often has evidence of cerebral atrophy [14]. Pyrimethamine, sulfadiazine, and folinic acid are used with surgical intervention reserved for diagnostic biopsy in cases where the diagnosis is unclear or for relief of mass effect. The prognosis of toxoplasmosis involving the CNS, particularly in those who are immunocompromised, is poor [48, 49, 50]. Early diagnosis and aggressive treatment are essential to obtain the best outcome. Prevention is fundamental in reducing both congenital and acquired toxoplasmosis. Recommendations include avoiding contact with cat litter, cooking meat to higher than 150 °F, washing fruit and vegetables thoroughly, and cleaning cooking surfaces carefully.

Neurocysticercosis, caused by the larval stage of the helminthic tapeworm Taenia solium, is the most common CNS parasitic infestation in humans and the commonest cause of acquired epilepsy [51, 52]. Cysticercosis is widely endemic in the developing world where pork is consumed and sanitation is poor, especially in Central and South America, non-Islamic regions of Asia and sub-Saharan Africa [53]. In certain developed countries, the prevalence may be influenced by the increasing migrant workforce [53, 54, 55, 56, 57, 58, 59, 60, 61]. The life cycle of T. solium involves humans as definitive hosts and pigs as intermediate hosts. The cycle is completed when a human inadvertently consumes measly pork, contaminated with viable T. solium eggs, which enter the mucosa of the small intestine, mature and then spread hematogenously to the muscle, brain, and skin [62, 63]. Once it enters the brain parenchyma, development occurs through four identifiable phases: vesicular phase—viable cyst with minimal host response; colloidal phase—degenerating cyst ruptures into surrounding parenchyma and incites a strong immune response; granular-nodular phase—further degeneration, forming a nodular cyst; and calcified phase—cyst dies and calcifies [64].

Immunocompromised patients appear more susceptible to multiorgan involvement, with HIV coinfection in neurocysticercosis increasing the risk of basilar meningitis and the formation of giant cysts [65, 66]. A useful classification for neurocysticercosis is based on viability and location: active—parasite is alive, transitional—degenerating parasite, and inactive—parasite is dead [64]. Each of these can be subclassified into parenchymal and extraparenchymal, i.e., meningeal, intraventricular, and subarachnoid forms [50, 62]. Cysticercus cellulosae is used to describe thin walled 3–20 mm sized cysts within the parenchyma, and Cysticercus racemosus refers to larger, “grape-like” vesicles mostly located in the subarachnoid cisterns, ventricles, or sylvian fissure [63, 67]. Clinically manifestation of neurocysticercosis depends on the size, number, location, and developmental stage of the cysticerci and also the host immune response [63]. Parenchymal lesions present with seizures or focal neurological deficits caused by direct compression. Cranial nerve palsies may be caused by vasculitis or fibrous adhesions. Intraventricular or cisternal lesions usually present with raised intracranial pressure and hydrocephalus resulting from obstruction of CSF flow due to widespread arachnoiditis and adhesions [68]. Other neurological sequelae include neurocognitive impairment, altered mental state, brainstem dysfunction, stroke-like symptoms, and extrapyramidal signs [69]. Proposed diagnostic criteria have been based on objective clinical, imaging, immunological, and epidemiological data [65]. In a hospital setting, neuroimaging remains the mainstay, with definitive diagnosis made on the basis of histopathologic evidence.

Lateral X-rays of the thigh and calf may demonstrate cigar-shaped calcifications. CT scans during the active phase of the disease reveal single or multiple hypodense lesions of varying sizes with a hyperdense mural nodule (Fig. 3). Ring enhancement suggests perilesional inflammation, and calcification denoting inactive lesions may be present in about 50% of cases. MRI is more reliable in demonstrating smaller cysts in the ventricles and subarachnoid spaces, with distinctive features on both T1- and T2-weighted imaging [66].
Fig. 3

Multiple active intracranial parenchymal neurocysticercal lesions

CSF mononuclear pleocytosis with raised protein and decreased glucose is typical with extraparenchymal disease [70]. Enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunoelectrotransfer blot (EITB) are the most widely used immunodiagnostic methods for diagnosing human cysticercosis [71]. In children with a single intracerebral lesion, EITB can yield false-negative results in 75% of cases; serological results, therefore, need to be interpreted together with clinical and radiological findings [72].

Treatment for neurocysticercosis includes antiparasitic agents, symptomatic medication, and surgery. Antihelminthic drugs praziquantel and albendazole are generally considered as part of long-term seizure control and for persisting/enlarging parenchymal lesions. They should be used with caution in cases of raised ICP, as the inflammatory response they evoke could precipitate further neurologic deterioration [73]. Albendazole is preferred over praziquantel, which has a lower efficacy on extraparenchymal lesions, interacts with steroids and antiepileptics, and may increase the risk of stroke [74, 75, 76]. Corticosteroids together with antihelminthics are recommended to reduce the inflammatory reaction induced by death of the larvae. First-line antiepileptic drugs remain the primary therapy for seizure control in neurocysticercosis [73], with gradual reduction in the medication after resolution on imaging studies recommended [52, 53, 54]. Standard treatment regimens appear effective in immunocompromised patients as well; however, the impact of antiretroviral therapy and immune reconstitution remains uncertain [77].

Neurosurgical interventions are required for confirming tissue diagnosis, relieving mass effect, and treating raised ICP and CSF diversion for hydrocephalus. Hydrocephalus may require insertion of an EVD as a temporizing measure. VPS failure rates in neurocysticercosis are reported as high as 67% [78]. Endoscopic approaches have gained increasing popularity for removing ventricular neurocysts and treating hydrocephalus [79, 80, 81]. The eradication of cysticercosis is dependent on improvement of human sanitation and public health infrastructure.

Amebic encephalitis in humans was first reported in 1965 [82]. Free-living amoebae thrive in warm water environments, and those causing CNS infection include Balamuthia mandrillaris, Entameba histolytica, and Naegleria fowleri. While amoebic encephalitis is rare, it is unfortunately almost always fatal. N. fowleri usually leads to primary amebic meningoencephalitis (PAM), while the other amoebae usually lead to granulomatous amebic encephalitis (GAE). PAM typically presents with fever, severe headache, and symptoms of raised ICP within a fortnight of exposure to contaminated water. GAE usually has a more protracted course, lasting weeks to months, often as an opportunistic infection in immunocompromised, HIV-infected patients [83]. The symptoms are initially non-specific, progressing to altered mental status and focal neurological deficit, eventually proving fatal within several weeks. Diagnosis depends on a focused history, asking for recent exposure to stagnant water bodies, clinical examination, imaging features, and identification of the organism on wet smear [24, 84]. Treatment should be aggressive and include antimicrobials such as, amphotericin B and metronidazole. Steroids and osmolar therapy should be considered for raised ICP. Surgery may be necessary in cases with space-occupying lesions and raised ICP.

Cerebral malaria, although not routinely considered an opportunistic infection, immunosuppression may have a negative impact on its natural history [85]. Even with treatment and supportive care, cerebral malaria has a reported mortality rate of 20–50%, with most reported fatalities occurring in African children [24, 86]. Fever is the clinical hallmark of cerebral malaria, while other diagnostic features include coma, seizures, identification of Plasmodium falciparum or Plasmodium vivax on blood smear, and exclusion of other causes of encephalopathy [87]. Management includes adequate resuscitation, supportive care, and commencement of antimalarial treatment, the details of which fall outside the scope of this article.

Fungal infections

Fungal invasion of the CNS generally results in subacute or chronic meningitis, encephalitis, parenchymal brain abscesses/granulomas, or vasculitis [88]. The diagnosis is usually made in a vulnerable patient with a history of exposure, confirmed by serological tests, CSF analysis or histopathological examination. Treatment usually requires long-term antifungal medication and CSF diversion in patients who develop hydrocephalus. Some of the more common CNS fungal infections are briefly discussed below [89].

Cryptococcosis—CNS infection with Cryptococcus neoformans species—remains one of the most common opportunistic infections in immunocompromised patients [90]. The clinical presentation is typical of meningitis, with severe, often unbearable headache, malaise, with or without fever [88] and usually follows a subacute or chronic course with features of raised ICP. Laboratory diagnosis is usually made using India ink stain or serological testing (Cryptococcal latex antigen test—CLAT). Recommended treatment differs in HIV infection, but generally includes amphotericin B with flucytosine (for 2 weeks), followed by oral fluconazole for 8 weeks. Raised ICP can be managed with serial lumbar punctures, though a lumboperitoneal shunt may be required in patients who develop hydrocephalus [16, 91].

CNS aspergillosis is usually caused by the organism Aspergillus fumigatus. Infection most commonly presents as an abscess and less commonly as meningitis (Fig. 4a, b). Excision of these lesions is recommended, as they may cause vascular invasion and can lead to the formation of mycotic aneurysms. Combination therapy with antifungal drugs and surgery has improved outcome [92].
Fig. 4

a, b CT scan demonstrating left parietal Aspergillus brain abscess, pre- and post contrast

Histoplasmosis is a systemic mycosis acquired via the respiratory system. CNS involvement may be a manifestation of disseminated disease or may be an isolated illness [93]. Neurologic syndromes include subacute or chronic meningitis and focal lesions (histoplasmosis). Positive diagnosis requires CSF (at least 10 ml), meningeal, or brain tissue [93]. Optimal treatment for CNS histoplasmosis is presently unclear, but amphotericin B and fluconazole are the main options.

In Coccidioidomycosis, CNS infection with the dimorphic fungus Coccidioides immitis, mostly seen in immunocompromised patients, leads to basal meningitis, often with hydrocephalus.

Early shunt placement is often required, together with antifungal therapy [94].

Sporotrichosis very rarely involves the CNS, but cases of meningitis have been described in HIV-infected patients. Imaging usually reveals non-enhancing lesions in the brainstem, basal ganglia, thalamus, and centrum semiovale, with meningeal enhancement [95]. Amphotericin B remains the treatment option for meningitis.

Candida species, while less virulent than Aspergillus, are the most common pathogen in patients with end-stage HIV. They often colonize central lines, external ventricular drains, and shunts. They can, therefore, either complicate the treatment of underlying hydrocephalus or be the causative organism [96]. Prevention of fungal colonization and control of local disease are important as prior colonization with Candida is a major risk factor to developing systemic candidiasis [97].

Viral infections

Cytomegalovirus (CMV) is acquired early in life and usually remains in latent state. In immunocompromised patients, primary infection with CMV can cause significant morbidity [98, 99]. The predominant presentation with CMV in immunocompromised patients is retinitis, and funduscopic examination usually confirms the diagnosis. Antiviral agents have been used for prophylaxis and treatment of CMV.

While other viral infections caused by Herpes simplex 2 (HSV2), Epstein-Barr virus, and JC virus (progressive multifocal leukoencephalopathy—PML) have been described, they very rarely cause CNS infection in children and have been included for completeness only.

Conclusion

The management of CNS infection in the immunocompromised child remains a challenge to most pediatric neurosurgeons. An awareness of the most common pathogens and the treatment modalities peculiar to these infections remains fundamental to optimal management.

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Algar V, Novelli V (2007) Infections in the immunocompromised host. Paediatr Child Health 17(4):132–136CrossRefGoogle Scholar
  2. 2.
    Allen UD (2016) Management of infections in the immunocompromised child: general principles. LymphoSign J 3(3):87–98CrossRefGoogle Scholar
  3. 3.
    Tulius M, Silva T, Grinsztejn B (2009) Opportunistic infections in the brain in developing countries. In: Paul RH et al. (eds) HIV and the brain, Current clinical neurology, pp 293–318Google Scholar
  4. 4.
    Bonilla FA, Geha RS (2003) Primary immunodeficiency diseases. J Allergy Clin Immunol 111:S571–S581CrossRefPubMedGoogle Scholar
  5. 5.
    Chinen J, Shearer WT (2010) Secondary immunodeficiencies including HIV infection. J Allergy Clin Immunol 125(2):S195–S203CrossRefPubMedGoogle Scholar
  6. 6.
    Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163(9):1009–1021CrossRefPubMedGoogle Scholar
  7. 7.
    Kumar V, Abbas AK, Fausto N, Aster JC (2010) In: Robbins and Cotran pathologic basis of disease, 8th edn. Saunders Elsevier, PhiladelphiaGoogle Scholar
  8. 8.
    Fieggen AG, Padayachy L (2015) Tuberculosis, parasitic and fungal infestations. In: Principles and practice of pediatric neurosurgery, 3rd edn. ThiemeGoogle Scholar
  9. 9.
    Thwaites GE, Lan NT, Dung NH et al (2005) Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 192(1):79–88CrossRefPubMedGoogle Scholar
  10. 10.
    Figaji AA, Fieggen AG (2010) The neurosurgical and acute care management of tuberculous meningitis: evidence and current practice. Tuberculosis 90:393–400CrossRefPubMedGoogle Scholar
  11. 11.
    Lammie GA, Hewlett RH, Schoeman JF, Donald PR (2009) Tuberculous cerebrovascular disease: a review. J Inf Secur 59:156–166Google Scholar
  12. 12.
    Campbell IA, Bah-Sow O (2006) Pulmonary tuberculosis: diagnosis and treatment. BMJ 332(7551):1194–1197CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wait JW, Schoeman JF (2009) Behaviour profiles after tuberculous meningitis. J Trop Pediatr 56(3):166–171CrossRefPubMedGoogle Scholar
  14. 14.
    Chang L, Cornford ME, Chiang FL, Ernst TM, Sun NC, Miller BL (1995) Radiologic-pathologic correlation. Cerebral toxoplasmosis and lymphoma in AIDS. Am J Neuroradiol 16(8):1653–1663PubMedGoogle Scholar
  15. 15.
    Andronikou S, Wieselthaler N, Smith B, Douis H, Fieggen AG, van Toorn R, Wilmshurst J (2005) Value of early follow-up CT in paediatric tuberculous meningitis. Pediatr Radiol 35:1092–1099CrossRefPubMedGoogle Scholar
  16. 16.
    Idro R, Newton C (2005) Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 4:827–840CrossRefPubMedGoogle Scholar
  17. 17.
    Tandon V, Mahapatra AK (2011) Management of post-tubercular hydrocephalus. Childs Nerv Syst 27:1699–1707CrossRefPubMedGoogle Scholar
  18. 18.
    Rajshekhar V (2009) Management of hydrocephalus in patients with tuberculous meningitis. Neurol India 57(4):368–374CrossRefPubMedGoogle Scholar
  19. 19.
    Bullock MRR, van Dellen JR (1982) The role of cerebrospinal fluid shunting in tuberculous meningitis. Surg Neurol 18:274–277CrossRefPubMedGoogle Scholar
  20. 20.
    Lamprecht D, Schoeman J, Donald P, Hartzenberg H (2001) Ventriculoperitoneal shunting in childhood tuberculous meningitis. Br J Neurosurg 15(2):119–125CrossRefPubMedGoogle Scholar
  21. 21.
    Sil K, Chatterjee S (2008) Shunting in tuberculous meningitis: a neurosurgeon’s nightmare. Childs Nerv Syst 24(9):1029–1032CrossRefPubMedGoogle Scholar
  22. 22.
    Palur R, Rajshekar V, Chandy MJ, Joseph T, Abraham J (1991) Shunt surgery for hydrocephalus in tuberculous meningitis: a long-tem follow-up study. J Neurosurg 74:64–69CrossRefPubMedGoogle Scholar
  23. 23.
    Figaji AA, Fieggen AG (2013) Endoscopic challenges and applications in tuberculous meningitis. World Neurosurg 79(2):S24–Se9CrossRefPubMedGoogle Scholar
  24. 24.
    Singh P, Kochhar R, Vashishta RK, Khandelwal N, Prabhakar S, Mohindra S, Singhi P (2006) Amoebic meningoencephalitis: spectrum of imaging findings. Am J Neuroradiol 27(6):1217–1221PubMedGoogle Scholar
  25. 25.
    Mathew JM, Rajshekar V, Chandy MJ (1998) Shunt surgery in poor grade patients with tuberculous meningitis and hydrocephalus: effects of response to external ventricular drainage and other variables on long-term outcome. J Neurol Neurosurg Psychiatry 65:115–118CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Peltzer K, Naidoo P, Matseke G, Louw J, Mchunu G, Tutshana B (2012) Prevalence of psychological distress and associated factors in tuberculosis patients in public primary care clinics in South Africa. BMC Psychiatry 12(1):89CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jonathan A, Rajshekhar V (2005) Endoscopic third ventriculostomy for chronic hydrocephalus after tuberculous meningitis. Surg Neurol 63:32–35CrossRefPubMedGoogle Scholar
  28. 28.
    Janku J (1923) Pathogenesa a pathologicka anatomie tak nazveneho vrozeneho kolobomu slute skvrny v oku normalne velikem a mikrophthalmickem s nalezem parazitu v sitnici. Cas Lek Cesk 60:1021.20Google Scholar
  29. 29.
    Grant A (1996) Varicella infection and toxoplasmosis in pregnancy. J Perinat Neonatal Nurs 10:17–29CrossRefPubMedGoogle Scholar
  30. 30.
    Desmonts G, Couvreur J (1979) Congenital toxoplasmosis: a prospective study of the offspring of 54 women who acquired toxoplasmosis during pregnancy: pathophysiology of congenital disease. In: Thalhammer O, Baumgarten K, Pollak A (eds) Perinatal medicine. George Thieme, StuttgartGoogle Scholar
  31. 31.
    Arnold SJ, Kinney MC, McCormick MS, Dummer S, Scott MA (1997) Disseminated toxoplasmosis. Unusual presentations in the immunocompromised host. Arch Pathol Lab Med 121(8):869–873PubMedGoogle Scholar
  32. 32.
    Conley FK, Jenkins HT, Remington JS (1981) Toxoplasma gondii infection of the central nervous system: use of peroxidise-antiperoxidase method to demonstrate toxoplasma in formalin fixed paraffin embedded tissue sections. Hum Pathol 12:690–698CrossRefPubMedGoogle Scholar
  33. 33.
    Patel DV, Hofels E, Vogel N et al (1996) Resolution of intracerebral calcification in children with treated congenital toxoplasmosis. Radiology 199:433–440CrossRefPubMedGoogle Scholar
  34. 34.
    Luft BJ, Conley F, Remington JS (1983) Outbreak of central nervous system toxoplasmosis in Western Europe and North America. Lancet 1:781–784CrossRefPubMedGoogle Scholar
  35. 35.
    Diebler C, Dussler A, Dulac O (1985) Congenital toxoplasmosis: clinical and neuroradiological evaluation of the cerebral lesions. Neuroradiology 27:125–130CrossRefPubMedGoogle Scholar
  36. 36.
    Remington JS, Mcleod R, Thuliez P et al (2006) Toxoplasmosis. In: Js R, Klein JO, Wilson CB et al (eds) Infectious diseases of the fetus and newborn, 6th edn. W.B. Saunders, Philadelphia, pp 947–1092CrossRefGoogle Scholar
  37. 37.
    McCauley JB, Boyer KM, Remington JS, Mcleod RL (2009) Toxoplasmosis. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (eds) Textbook of pediatric infectious diseases, 6th edn. WB Saunders, Philadelphia, pp 2954–2971Google Scholar
  38. 38.
    Desmonts G, Daffos F, Forrestier F et al (1985) Prenatal diagnosis of congenital toxoplasmosis. Lancet 1:500–504CrossRefPubMedGoogle Scholar
  39. 39.
    Hohlfeld P, Daffos T, Costa JM et al (1994) Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain reaction test on amniotic fluid. N Engl J Med 331:695–699CrossRefPubMedGoogle Scholar
  40. 40.
    Foulon W, Villena I, Stray-Pederson B et al (1999) Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol 180:410–415CrossRefPubMedGoogle Scholar
  41. 41.
    Wilson CB, Remington JS, Stagno S, Reynolds DW (1980) Development of adverse sequelae in children born with subclinical congenital toxoplasma infection. Pediatrics 66:767–774PubMedGoogle Scholar
  42. 42.
    Roizen N, Swisher CN, Stein M, Hopkins J, Boyer KM, Holfels E, Mets MB, Stein L, Patel D, Meier P (1995) Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 95:11–20PubMedGoogle Scholar
  43. 43.
    Mitchell CD, Erlich SS, Mastrucci MT, Hutto SC et al (1990) Congenital toxoplasmosis occurring in infants perinatally infected with human immunodeficiency virus 1. Pediatr Infect Dis J 9:512–518CrossRefPubMedGoogle Scholar
  44. 44.
    Martinovic J, Sibalic D, Djordjevic M et al (1982) Frequency of toxoplasmosis in the appearance of congenital hydrocephalus. J Neurosurg 56:830–834CrossRefPubMedGoogle Scholar
  45. 45.
    Stahl W, Kaneda Y (1997) Pathogenesis of murine toxoplasmic hydrocephalus. Parasitology 114:219–229CrossRefPubMedGoogle Scholar
  46. 46.
    Porter SB, Sende MA (1992) Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome.1992;327:1643–8Google Scholar
  47. 47.
    Holliman RE (1988) Toxoplasmosis and the acquired immune deficiency syndrome. J Inf Secur 16:121–128Google Scholar
  48. 48.
    Townsend JJ, Wolinsky JS, Baringer JR, Johnson PC (1975) Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol 32:335–343CrossRefPubMedGoogle Scholar
  49. 49.
    Arendt G, von Giesen HJ, Hefter H, Neuen-Jacob E, Roick H, Jablonowski H (1999) Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand 100:178–184CrossRefPubMedGoogle Scholar
  50. 50.
    Walker M, Zunt JR (2005) Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 40(7):1005–1015CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Mitchell WG (1999) Neurocysticercosis and acquired cerebral toxoplasmosis in children. Semin Pediatr Neurol 6:267–277CrossRefPubMedGoogle Scholar
  52. 52.
    Medina MT, DeGiorgio C (2002) Introduction to neurocysticercosis: a worldwide epidemic. Neurosurg Focus 12(6)Google Scholar
  53. 53.
    Del Brutto OH, Santibanez R, Noboa CA et al (1992) Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 42:389–392CrossRefPubMedGoogle Scholar
  54. 54.
    Carpio A, Escobar A, Hauser WA (1998) Cysticercosis and epilepsy: a critical review. Epilepsia 39:1025–1040CrossRefPubMedGoogle Scholar
  55. 55.
    Carpio A (2002) Neurocysticercosis: an update. Lancet Infect Dis 2:751–762CrossRefPubMedGoogle Scholar
  56. 56.
    Cao W, van der Ploeg CPB, Xu J et al (1997) Risk factor for human cysticercosis morbidity: a population based case-control study. Epidemiol Infect 119:231–235CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Sanchez AL, Lindback J, Schantz PM et al (1999) A population-based, case control study of Taenia solium taeniasis and cysicersosis. Ann Trop Med Parasitol 93(3):247–258CrossRefPubMedGoogle Scholar
  58. 58.
    Schantz PM, Moore AC, Muńoz JL et al (1992) Neurocysticercosis in an orthodox Jewish community in New York City. NEJM 327:692–695CrossRefPubMedGoogle Scholar
  59. 59.
    Pawlowski ZS (2002) Taenia solium: basic biology and transmission. In: Singh G, Prabhakar S (eds) Taenia solium cysticercosis. CABI Publishing, Wallingford, pp 1–23Google Scholar
  60. 60.
    Escobar A (1983) The pathology of neurocysticercosis. In: Palcios E, Rodriguez-Carbajal, Taveras JM (eds) Cysticercosis of the central nervous system. Charles C. Thomas, Springfield, pp 27–54Google Scholar
  61. 61.
    Sanz CR (1987) Host response in childhood neurocysticercosis: some pathological aspects. Childs Nerv Syst 3(4):206–207CrossRefPubMedGoogle Scholar
  62. 62.
    Carpio A, Placencia M, Santillán F, Escobar A (1994) Proposal for a new classification of neurocysticercosis. Can J Neurol Sci 21:43–47CrossRefPubMedGoogle Scholar
  63. 63.
    Estanol B, Corona T, Abad P (1986) A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry 49:1131–1134CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Pitella JEH (1997) Neurocysticercosis. Brain Pathol 7:681–693CrossRefGoogle Scholar
  65. 65.
    White AC (2000) Neurocysticercosis. Curr Treat Options Infect Dis 2:78–87Google Scholar
  66. 66.
    Del Brutto OH, Rajshekhar V, White AC et al (2001) Proposed diagnostic criteria for neurocysticercosis. Neurology 57:177–183CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Schantz PM, Wilkins PP, Tsang VCW (1998) Immigrants, imaging, and immunoblots: the emergence of neurocysticercosis as a significant public health problem. In: Scheld WM, Craig WA, Hughes JM (eds) Emerging infections. ASM Press, Washington DC, pp 213–242CrossRefGoogle Scholar
  68. 68.
    Jena A, Sanchatee PC, Gupta RK et al (1998) Cysticercosis of the brain shown by magnetic resonance imaging. Clin Radiol 39:542–546CrossRefGoogle Scholar
  69. 69.
    Sinha S, Sharma BS (2009) Neurocysticercosis: a review of current status and management. J Clin Neurosci 16:867–876CrossRefPubMedGoogle Scholar
  70. 70.
    Rajshekhar V (2003) Solitary cerebral cysticercus granuloma. Epilepsia 44(Suppl):25–28CrossRefGoogle Scholar
  71. 71.
    Bittencourt PRM, Costa AJ, Oliveira TV, Gracia CM, Gorz AM, Mazer S (1990) Clinical, radiological and cerebrospinal fluid presentation of neurocysticercosis: a prospective study. Arq Neuropsiquiatr 48:286–289CrossRefPubMedGoogle Scholar
  72. 72.
    Tsang VW, Brand JA, Boyer AE (1989) An enzyme-linked immunoelectrotransfer blot assay and glycoproteins antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 174:1007–1009Google Scholar
  73. 73.
    St Geme JW III, Maldonado YA, Enzmann D et al (1993) Consensus: diagnosis and management of neurocysticercosis in children. Pediatr Infect Dis J 12:455–461CrossRefPubMedGoogle Scholar
  74. 74.
    Garcia HH, Carlton A, Evans W, Nash TE et al (2002) Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 15(4):747–756CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Takayanagui OM, Jardim E (1992) Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 49:290–294CrossRefPubMedGoogle Scholar
  76. 76.
    Sotelo J, Escobedo F, Panegos P (1988) Albendazole vs praziquantel therapy for neurocysticercosis. A controlled trial. Arch Neurol 45:532–534CrossRefPubMedGoogle Scholar
  77. 77.
    Thornton CA, Houston S, Latif AS (1992) Neurocysticercosis and human immunodeficiency virus infection: a possible association. Arch Neurol 49:963–965CrossRefPubMedGoogle Scholar
  78. 78.
    Woo E, Yu L, Huang CY (1988) Cerebral infarct precipitated by praziquantel in neurocysticercosis: a cautionary note. Trop Geogr Med 40:143–146PubMedGoogle Scholar
  79. 79.
    Kelly R, Duong DH, Locke GE (2002) Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 50:757–762CrossRefGoogle Scholar
  80. 80.
    Husain M, Jha DK, Rastogi M, Husain N, Gupta RK (2007) Neuro-endoscopic management of intraventricular neurocysticercosis (NCC). Acta Neurochir 149:341–346CrossRefPubMedGoogle Scholar
  81. 81.
    Anandh B, Mohanty A, Sampath S, Praharaj SS, Kolluri S (2001) Endoscopic approach to intraventricular cysticercal lesions. Minim Invasive Neurosurg 44:194–196CrossRefPubMedGoogle Scholar
  82. 82.
    Cavalheiro S, Zymberg ST, Teixera PD, Da Silva MC (2004) Hydrocephalus in neurocysticercosis and other parasitic and infectious diseases. In: Cinalli G, Maixner WJ, Saint-Rose C (eds) Pediatric hydrocephalus, vol 17. Springer-Verlag, Milan, pp 1–14Google Scholar
  83. 83.
    Fowler M, Carter RF (1965) Acute pyogenic meningitis probably due to Acanthamoeba sp.: a preliminary report. BMJ:740–742Google Scholar
  84. 84.
    Anzil AP, Rao C, Wrzolek MA, Visvesvara GS, Sher JH, Kozlowski PB (1991) Amebic meningoencephalitis in a patient with AIDS caused by a newly recognised opportunistic pathogen, Leptomyxid ameba. Arch Pathol Lab Med 115:21–25PubMedGoogle Scholar
  85. 85.
    Harms G, Feldmeier H (2005) The impact of HIV infection on tropical diseases. Infect Dis Clin N Am 19(1):121–135CrossRefGoogle Scholar
  86. 86.
    Phillips RE, Solomon T (1990) Cerebral malaria in children. Lancet 336:1355–1360CrossRefPubMedGoogle Scholar
  87. 87.
    Greenwood BM (1997) The epidemiology of malaria. Ann Trop Med Parasitol 91:763–769CrossRefPubMedGoogle Scholar
  88. 88.
    Satishchandra P, Mathew T, Gadre G, Nagarathna S, Chandramukhi A, Mahadevan A, Shankar SK (2007) Cryptococcal meningitis: clinical, diagnostic and therapeutic overviews. Neurol India 55:226–232CrossRefPubMedGoogle Scholar
  89. 89.
    Bruckner DA, Kokkinos HM (2009) Classification of fungi. In: Feigin and Cherry’s textbook of pediatric infectious diseases, vol 2. Saunders, Elsevier, pp 2715–2736Google Scholar
  90. 90.
    Mohar A, Romo J, Salido F, Jessurun J, de León SP, Reyes E, Volkow P, Larraza O, Peredo MA, Cano C, Gomez G, Sepúlveda J, Mueller N (1992) The spectrum of clinical and pathological manifestation of AIDS in a consecutive series of autopsied patients in Mexico. AIDS 6(5):467–473CrossRefPubMedGoogle Scholar
  91. 91.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50:291–322CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Baddley JW, Dismukes WE (2003) Cryptococcosis. In: Dismukes W, Pappas PG, Sobel JD (eds) Clinical mycology. Oxford University Press, New York, pp 188–205Google Scholar
  93. 93.
    Couppie P, Aznar C, Carme B et al (2006) American Histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis 19(5):443–449CrossRefPubMedGoogle Scholar
  94. 94.
    Ruhnke M, Grzegorz K, Otto K, Schwartz S (2007) CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 21(8):659–676CrossRefPubMedGoogle Scholar
  95. 95.
    Donabedian H, O’Donnell E, Olszzewski C et al (1994) Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn Microbiol Infect Dis 18(2):111–115CrossRefPubMedGoogle Scholar
  96. 96.
    Williams P (2007) Coccidioidal meningitis. Ann N Y Acad Sci 1111:377–384CrossRefPubMedGoogle Scholar
  97. 97.
    Potter M (2005) Strategies for managing systemic fungal infections and the place of itraconazole. J Antimicrob Chemother 56(Suppl 1):i49–i59CrossRefPubMedGoogle Scholar
  98. 98.
    Emery VC (2001) Investigation of CMV disease in immunocompromised patients. J Clin Pathol 54:84–88CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Reuter JD, Gomez DL, Wilson JH, van den Pol AN (2004) Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J Virol 78:1473–1487CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Neurosurgery, Neurosciences Institute, Faculty of Health SciencesUniversity of Cape TownCape TownSouth Africa

Personalised recommendations